AB Science SA

AB Science - Clarification following the February 11, 2022 public hearing of the Enforcement Committee of the French Market Regulator (AMF)

12 2 2022 14:49:07 提供 Nasdaq GlobeNewswire

AB Science to present on its Amyotrophic Lateral Sclerosis (ALS) development program at the 2022 ALS Drug Development Summit

07 2 2022 12:12:11 提供 Nasdaq GlobeNewswire

AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the Swedish Medical Products Agency

02 2 2022 12:13:01 提供 Nasdaq GlobeNewswire

AB Science has been granted authorization to initiate Phase II study in patients with severe mast cell activation syndrome by the French Health Authority (ANSM)

19 1 2022 12:02:50 提供 Nasdaq GlobeNewswire

AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the French Health Authority (ANSM)

03 1 2022 12:10:59 提供 Nasdaq GlobeNewswire

AB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus

29 11 2021 14:57:09 提供 Nasdaq GlobeNewswire

AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia

22 11 2021 12:20:45 提供 Nasdaq GlobeNewswire

AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS

18 11 2021 14:40:53 提供 Nasdaq GlobeNewswire

AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)

18 10 2021 12:14:05 提供 Nasdaq GlobeNewswire

AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)

04 10 2021 12:10:54 提供 Nasdaq GlobeNewswire

AB Science today reports its revenues for the first half of 2021 and provides an update on its activities

30 9 2021 13:21:10 提供 Nasdaq GlobeNewswire

AB Science receives regulatory authorization to commence a second Phase 2 Covid-19 study

28 9 2021 13:25:22 提供 Nasdaq GlobeNewswire

AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the treatment of Acute Myeloid Leukemia (AML)

22 9 2021 12:09:23 提供 Nasdaq GlobeNewswire

AB Science announced that an abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurology

20 9 2021 13:15:45 提供 Nasdaq GlobeNewswire

AB Science announced today that it has received authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19 (AB20001)

16 9 2021 13:34:08 提供 Nasdaq GlobeNewswire

AB Science announced that it has received new authorizations to resume patient enrollment in its Phase 3 studies of masitinib

14 9 2021 12:01:33 提供 Nasdaq GlobeNewswire

AB Science announced today that results from masitinib study AB12003 in prostate cancer have been presented at the 2021 American Urological Association

13 9 2021 12:04:50 提供 Nasdaq GlobeNewswire

AB Science announced today that latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND

02 9 2021 11:59:01 提供 Nasdaq GlobeNewswire

AB Science announces that it has received a second authorization to resume patient enrollment, in the Phase 3 study of masitinib in mastocytosis

25 8 2021 12:46:55 提供 Nasdaq GlobeNewswire

AB Science announces that it has received the first authorization to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in ALS

23 8 2021 13:43:09 提供 Nasdaq GlobeNewswire